Markov modeling in hepatitis B screening and linkage to care

[1]  K. M. Owolabi.  Numerical solution of diffusive HBV model in a fractional medium , 2016, SpringerPlus.

[2]  S. Hutchinson,et al.  Cost-Effectiveness of HBV and HCV Screening Strategies – A Systematic Review of Existing Modelling Techniques , 2015, PloS one.

[3]  M. Bility,et al.  Modeling hepatitis B virus infection, immunopathology and therapy in mice. , 2015, Antiviral research.

[4]  Vyas Ramanan,et al.  Modeling host interactions with hepatitis B virus using primary and induced pluripotent stem cell-derived hepatocellular systems , 2014, Proceedings of the National Academy of Sciences.

[5]  Hao Jiang,et al.  Population health impact and cost‐effectiveness of monitoring inactive chronic hepatitis B and treating eligible patients in Shanghai, China , 2014, Hepatology.

[6]  R. Gish,et al.  A simple and inexpensive point-of-care test for hepatitis B surface antigen detection: serological and molecular evaluation , 2014, Journal of viral hepatitis.

[7]  Chien-Jen Chen,et al.  Spontaneous seroclearance of hepatitis B seromarkers and subsequent risk of hepatocellular carcinoma , 2013, Gut.

[8]  R. Peeling,et al.  Rapid Point-of-Care First-Line Screening Tests for Hepatitis B Infection: A Meta-Analysis of Diagnostic Accuracy (1980–2010) , 2012, The American Journal of Gastroenterology.

[9]  K. Kowdley,et al.  Prevalence of chronic hepatitis B among foreign‐born persons living in the United States by country of origin , 2012, Hepatology.

[10]  M. Krahn,et al.  Cost effectiveness of screening immigrants for hepatitis B , 2011, Liver international : official journal of the International Association for the Study of the Liver.

[11]  E. Schiff,et al.  Cost-effectiveness of screening for chronic hepatitis C infection in the United States. , 2011, Clinical Infectious Diseases.

[12]  Chien-Jen Chen,et al.  Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. , 2010, Gastroenterology.

[13]  R. D. de Man,et al.  Screening and early treatment of migrants for chronic hepatitis B virus infection is cost-effective. , 2010, Gastroenterology.

[14]  M. Brandeau,et al.  Cost‐effectiveness of nationwide hepatitis B catch‐up vaccination among children and adolescents in China , 2010, Hepatology.

[15]  R. D. de Man,et al.  Potential impact of long‐term nucleoside therapy on the mortality and morbidity of active chronic hepatitis B , 2009, Hepatology.

[16]  I. Hung,et al.  HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. , 2008, Gastroenterology.

[17]  G. Guyatt,et al.  GRADE: an emerging consensus on rating quality of evidence and strength of recommendations , 2008, BMJ : British Medical Journal.

[18]  L. Lacey,et al.  The cost-effectiveness of long-term antiviral therapy in the management of HBeAg-positive and HBeAg-negative chronic hepatitis B in Singapore , 2007, Journal of viral hepatitis.

[19]  M. Brandeau,et al.  Cost-Effectiveness of Screening and Vaccinating Asian and Pacific Islander Adults for Hepatitis B , 2007, Annals of Internal Medicine.

[20]  R. Gish,et al.  Chronic hepatitis B: current epidemiology in the Americas and implications for management , 2006, Journal of viral hepatitis.

[21]  D. Lavanchy,et al.  Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures , 2004, Journal of viral hepatitis.

[22]  R. Aggarwal,et al.  Assessment of cost-effectiveness of universal hepatitis B immunization in a low-income country with intermediate endemicity using a Markov model. , 2003, Journal of hepatology.

[23]  C. Chu,et al.  Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. , 2002, Gastroenterology.

[24]  A. Lok,et al.  Spontaneous hepatitis B e antigen to antibody seroconversion and reversion in Chinese patients with chronic hepatitis B virus infection. , 1987, Gastroenterology.

[25]  M. Eckman,et al.  The cost-effectiveness of screening for chronic hepatitis B infection in the United States. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  Yoshiyuki Suzuki,et al.  Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. , 2006, The American journal of medicine.

[27]  B. Nordstrom.  FINITE MARKOV CHAINS , 2005 .